A Study of Neoadjuvant Tislelizumab With SBRT in Patients With Resectable Hepatocellular Carcinoma

NCT05185531 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

COMBINATION_PRODUCT: PD-1 plus stereotactic body radiotherapy

Sponsor

Shandong Cancer Hospital and Institute

Collaborators

[object Object]